Differential electrophysiological changes in striatal output neurons in Huntington's disease

Journal of Neuroscience

Volumn 31, Issue 4, 2011, Pages 1170-1182

  André, Véronique M ^a   Cepeda, Carlos ^a   Fisher, Yvette E ^a   Huynh, My ^a   Bardakjian, Nora ^a   Singh, Sumedha ^a   Yang, X William ^a   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE AUTORECEPTOR; ENHANCED GREEN FLUORESCENT PROTEIN; GLUTAMIC ACID; QUINPIROLE; REMOXIPRIDE; TETRABENAZINE; TETRODOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN ELECTROPHYSIOLOGY; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; EXCITATORY POSTSYNAPTIC POTENTIAL; HUNTINGTON CHOREA; HYPOKINESIA; MALE; MEDIUM SIZED SPINY NEURON; MOUSE; NERVE CELL; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STEREOTYPY; SYNAPTIC TRANSMISSION;

ACTION POTENTIALS; AGE FACTORS; ANIMALS; CORPUS STRIATUM; DENDRITIC SPINES; DOPAMINE; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; GREEN FLUORESCENT PROTEINS; HUNTINGTON DISEASE; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; NEURONS; PROMOTER REGIONS, GENETIC; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR; SYNAPTIC TRANSMISSION; TETRABENAZINE;

EID: 79251570219     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3539-10.2011     Document Type: Article

References (60)

1. Albin RL, Reiner A, Anderson KD, Dure LS 4th, Handelin B, Balfour R, Whetsell WO Jr, Penney JB, Young AB (1992) Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 31:425-430.
2. André VM, Cepeda C, Cummings DM, Jocoy EL, Fisher YE, William Yang X, Levine MS (2010) Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci 31:14-28.
3. Antoniou K, Kafetzopoulos E, Papadopoulou-Daifoti Z, Hyphantis T, Marselos M (1998) D-amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats. Neurosci Biobehav Rev 23:189-196.
4. Benn CL, Slow EJ, Farrell LA, Graham R, Deng Y, Hayden MR, Cha JH (2007) Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience 147:354-372. (Pubitemid 46907444)
5. Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Hervé D, Valjent E, Girault JA (2008) Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 28:5671-5685.
6. Bird ED, Spokes EG, Iversen LL (1980) Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness. Acta Psychiatr Scand Suppl 280:63-73.
7. Bolam JP, Hanley JJ, Booth PA, Bevan MD (2000) Synaptic organisation of the basal ganglia. J Anat 196:527-542.
8. Bolivar VJ, Manley K, Messer A (2004) Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice. Brain Res 1005:29-35.
9. Bonelli RM, Hofmann P (2007) A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 8:141-153.
10. Brouillet E, Condé F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59:427-468.
11. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257. (Pubitemid 29174016)
12. Cepeda C, Buchwald NA, Levine MS (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A 90:9576-9580.
13. Cepeda C, Hurst RS, Calvert CR, Hernández-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23:961-969. (Pubitemid 36206187)
14. Cepeda C, Ariano MA, Levine MS (2004) Dopamine and glutamate in Huntington's disease. In: Dopamine and glutamate in psychiatric disorders (Schmidt WJ, Reith MEA, eds), pp 539-565. Totowa, NJ: Humana.
15. Cepeda C, Wu N, André VM, Cummings DM, Levine MS (2007) The corticostriatal pathway in Huntington's disease. Prog Neurobiol 81:253-271.
16. Cepeda C, André VM, Yamazaki I, Wu N, Kleiman-Weiner M, Levine MS (2008) Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci 27:671-682.
17. Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 13:277-280.
18. Choi S, Lovinger DM (1997) Decreased probability of neurotransmitter release underlies striatal long-term depression and postnatal development of corticostriatal synapses. Proc Natl Acad Sci U S A 94:2665-2670. (Pubitemid 27136933)
19. Crossman AR (2000) Functional anatomy of movement disorders. J Anat 196:519-525.
20. Cummings DM, André VM, Uzgil BO, Gee SM, Fisher YE, Cepeda C, Levine MS (2009) Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 29:10371-10386.
21. Dumartin B, Jaber M, Gonon F, Caron MG, Giros B, Bloch B (2000) Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proc Natl Acad Sci U S A 97:1879-1884.
22. Ferrante RJ, Kowall NW, Richardson EP Jr (1991) Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 11:3877-3887.
23. Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15:133-139.
24. Gertler TS, Chan CS, Surmeier DJ (2008) Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci 28:10814-10824.
25. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
26. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, Heintz N (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917-925.
27. Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR (2009) Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29:2193-2204.
28. Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227:770-773.
29. Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW (2008) Fulllength human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182-6195.
30. Graybiel AM, Aosaki T, Flaherty AW, Kimura M (1994) The basal ganglia and adaptive motor control. Science 265:1826-1831. (Pubitemid 24324235)
31. Hickey MA, Reynolds GP, Morton AJ (2002) The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J Neurochem 81:46-59.
32. Horvitz JC, Williams G, Joy R (2001) Time-dependent actions of D2 family agonist quinpirole on spontaneous behavior in the rat: dissociation between sniffing and locomotion. Psychopharmacology (Berl) 154:350-355.
33. Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366-372.
34. Johnson MA, Villanueva M, Haynes CL, Seipel AT, Buhler LA, Wightman RM (2007) Catecholamine exocytosis is diminished in R6/2 Huntington's disease model mice. J Neurochem 103:2102-2110. (Pubitemid 350126631)
35. Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS (2009) Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 29:2414-2427.
36. Kita T, Matsunari Y, Saraya T, Shimada K, O'Hara K, Kubo K, Wagner GC, Nakashima T (2000) Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int J Dev Neurosci 18:521-530. (Pubitemid 30406993)
37. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86:2667-2677.
38. Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445:643-647.
39. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev:CD006456.
40. Milnerwood AJ, Raymond LA (2007) Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol 585:817-831.
41. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65:178-190.
42. Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA (2010) Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J Neurochem 112:755-761.
43. Presti MF, Gibney BC, Lewis MH (2004) Effects of intrastriatal administration of selective dopaminergic ligands on spontaneous stereotypy in mice. Physiol Behav 80:433-439.
44. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85:5733-5737.
45. Richfield EK, Maguire-Zeiss KA, Vonkeman HE, Voorn P (1995) Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol 38:852-861.
46. Rudnick G, Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263. (Pubitemid 23290252)
47. Sanberg PR, Calderon SF, Giordano M, Tew JM, Norman AB (1989) The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp Neurol 105:45-53. (Pubitemid 19198876)
48. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555-1567.
49. Spielewoy C, Roubert C, Hamon M, Nosten-Bertrand M, Betancur C, Giros B (2000) Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol 11:279-290. (Pubitemid 30449759)
50. Sulzer D, Maidment NT, Rayport S (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60:527-535. (Pubitemid 23030947)
51. Tang TS, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signalingandstriatal neurodegeneration in Huntington's disease. J Neurosci 27:7899-7910.
52. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72:971-983. (Pubitemid 23110238)
53. Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JP, Benecke R, Marsden CD (1988) The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 111:223-244.
54. Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E (2000) Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199-203.
55. Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR (2005a) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:1379-1392.
56. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR (2005b) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:3823-3835.
57. Vetter JM, Jehle T, Heinemeyer J, Franz P, Behrens PF, Jackisch R, Landwehrmeyer GB, Feuerstein TJ (2003) Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum. J Neurochem 85:1054-1063. (Pubitemid 36578637)
58. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577.
59. Wu N, Cepeda C, Zhuang X, Levine MS (2007) Altered corticostriatal neurotransmission and modulation in dopamine transporter knock-down mice. J Neurophysiol 98:423-432. (Pubitemid 47084832)
60. Zucker RS (1989) Short-term synaptic plasticity. Annu Rev Neurosci 12:13-31.